MENU

Fox Chase Cancer Center News

Dr. Larry Kaiser, President and CEO of Temple University Health System (left) and Dr. Michael Seiden, President and CEO of Fox Chase Cancer Center, shake hands after closing on the final agreement that brings Fox Chase Cancer Center into Temple University Health System.
July 2, 2012

Temple University Health System Now Includes Fox Chase Cancer Center

(Philadelphia, PA) – As of July 1, 2012, Fox Chase Cancer Center became a part of Temple University Health System, one of Philadelphia’s leading academic health centers, providing access to quality care through its hospitals and multi-specialty satellite facilities while supporting excellence and innovation in education and research.   

Mark K. Buyyounouski, MD, MS
June 26, 2012

Fox Chase Cancer Center Launches Study for Novel Vaccine Aimed at Preventing Prostate Cancer Recurrence

PHILADELAPHIA, PA (June 26, 2012)—Surgery and radiation therapy are the two most common forms of treatment for newly diagnosed, non-metastatic prostate cancer. Now, an entirely new treatment for prostate cancer is under investigation at Fox Chase Cancer Center—a vaccine therapy called ProstAtak™.

David L Wiest, PhD
June 11, 2012

Highly Unusual Form of Inheritance Seen in Immune Disorder

PHILADELPHIA, PA (June 11, 2012)—The biological rule that people receive half of their genetic material from their fathers and half from their mothers does not always apply, it seems.

In the first such case on record, researchers at Fox Chase Cancer Center in Philadelphia have identified a child with a severe form of immune deficiency due to having received two copies of a disordered gene from his mother. Indeed, the child inherited two entire copies of the same chromosome, made up of thousands of genes, from his mother alone, with no contribution from his father.

Yu-Ning Wong, MD, MSCE
June 2, 2012

A Patient’s Socioeconomic Status May Predict their Preference in Treatment Options

CHICAGO, IL (June 2, 2012)––Though it would seem logical, cancer patients don’t always choose therapies with the best chance for survival—cost and side effects are also major considerations.   Little has been known about the extent to which cost and side effects influence a patient’s treatment decision.

Ranee Mehra, MD
June 2, 2012

New Therapy on the Horizon for ALK+ Non-Small Cell Lung Cancer

CHICAGO, IL (June 2, 2012)––A new compound that targets anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer is well-tolerated by patients and is already showing early signs of activity, including in patients who no longer respond to crizotinib—the only approved ALK inhibitor.  Results of this Novartis-sponsored sudy will be presented by a researcher from Fox Chase Cancer Center during the 2012 Annual Meeting of the American Society of Clinical Oncology on Sunday, June 3.  

Massimo Cristofanilli, MD, FACP
June 2, 2012

Fox Chase Researchers find that Combination Treatment with Lapatinib and Pazopanib Does Not Improve Outcomes for Patients with Inflammatory Breast Cancer

CHICAGO, IL (June 2, 2012)––Inflammatory breast cancer is a very aggressive type of cancer associated with early metastasis and poor survival rates, and the prognosis is even worse for patients with tumors expressing the ErbB2 receptor. The ErbB2-inhibiting drug lapatinib can slow the spread of cancer cells in individuals with advanced breast cancer who have already tried other chemotherapy medications.

June 2, 2012

Fox Chase Researchers Find That Not All Patients Will Pay for Genetic Testing

CHICAGO, IL (June 2, 2012)––More than one-fifth of people who have received referrals to test for cancer-causing genes say they will only undergo testing if their insurance covers the cost—just as more insurers are instituting cost-sharing for medical services like genetic testing, according to new findings from Fox Chase Cancer Center in Philadelphia released at this year's 2012 Annual Meeting of the American Society of Clinical Oncology on Saturday, June 2.

Elizabeth Plimack, MD, MS
June 2, 2012

Fox Chase Cancer Center Researchers Find that Accelerated Chemotherapy Given before Surgery Shows Benefit for Patients with Muscle-Invasive Bladder Cancer

CHICAGO, IL (June 2, 2012)––For some patients with muscle-invasive bladder cancer, treatment may begin before they undergo cystectomy, or surgical removal of the bladder. They may be advised by oncologists to receive chemotherapy before surgery. A large randomized clinical trial published in 2003 demonstrated a survival benefit for neoadjuvant, or pre-surgical, MVAC (methotrexate, vinblastine, doxorubicin and cisplatin) using a standard dose and schedule. However, in an effort to improve toxicity, standard MVAC has been essentially abandoned in favor of other regimens.

Pages

Connect with Fox Chase